Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
Conditions
Brief summary
Glaucoma is a progressive optic neuropathy that results in a loss of contrast sensitivity and visual field if not detected and treated. When glaucoma patients undergo cataract surgery, they are often not ideal candidates for many existing presbyopia correcting IOLs as they reduce contrast sensitivity because of the splitting of light and are more likely to have visual disturbances secondary to diffractive steps in the IOL design. This is largely because of a higher rate of ocular surface disease and meibomian gland dysfunction in this patient population due to the chronic utilization of topical drops. As a result of this, patients with glaucoma currently receive aspheric monofocal IOLs during cataract surgery, which are lenses with minimal loss of contrast sensitivity but only one point of focus (typically targeted for distance). This necessitates the use of glasses for near and intermediate vision and has an impact on quality of life for these patients. The Vivity Extended Depth of Focus (EDOF) IOL is a new technology that maintains uncompromised distance vision and provides improved intermediate vision correction, reducing the need for glasses. This lens uses a new optical system with no diffractive steps in the IOL; trials in non-glaucomatous patients have shown the rate of visual aberrations to be comparable to an aspheric monofocal IOL which are currently the standard of care in patients with glaucoma. There is no published data on outcomes of this IOL in patients with primary open angle glaucoma (POAG) or ocular hypertension (OHT). Studies are required to evaluate the clinical success of this new lens technology in glaucomatous patients. This will be the first study in Canada to report clinical outcomes of the Vivity IOL in this patient cohort.
Interventions
DEVICEVivity Extended Depth of Focus
Cataract surgery
Sponsors
Maisonneuve-Rosemont Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* Age greater than 18 years * Patients undergoing uncomplicated cataract surgery with IOL implantation * Patients with both eyes that calculate for IOL powers in the following ranges: 15-25D spherical power (for Vivity) * Patients possessing with-the-rule or against-the-rule astigmatism ≤2.50 D * Well controlled OAG or OHT defined as IOP less than or equal to 18mmHg * Mild to moderate glaucoma as defined by MD VF loss less than 12 dB and no VF defect within the central 5 degrees with 0dB or less than 15dB of both hemi-fields in the central 5 degrees
Exclusion criteria
* Ocular comorbidity that might hamper post-operative visual acuity (ie. Macular degeneration, macular edema, uveitis, corneal dystrophy, diabetic retinopathy) * Ocular trauma or zonula instability * Previous refractive surgery * Irregular corneal astigmatism and keratoconus * Difficulties comprehending written or spoken English or French language * Patients with physical or intellectual disability * Patients unable to fixate * Patients with uncontrolled glaucoma or advanced glaucoma * Patients that are undergoing filtration or tube surgery or MIGS devices for glaucoma * Patients with previous filtration or tube surgery for glaucoma * Patients with unreliable biometry * Severe dry eye disease or ocular surface disease * Patients where Barrett Toric Calculator recommends T5 or higher toric IOL
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Binocular uncorrected visual acuity | 3 months | Binocular uncorrected visual acuities at 6m distance will be measured |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Spectacle independence | 3 months | Spectacle independence will be evaluated using the IOLSAT questionnaire |
| IOP | 1 day | IOP will be measured in mmHg |
| IOP (mmHg at 1 day, 1 month and 3 months) | 3 months | IOP will be measured in mmHg |
| Severity, frequency of bothersomeness of starbursts, haloes, and glare | 3 months | Severity, frequency of bothersomeness of starbursts, haloes, and glare will be evaluated using the QUVID questionnaire |
| Refractive target accuracy | Approximate patient follow-up time is 4 months following phacoemulsification and insertion of the study lens in the second eye. Time in between eyes will be approximately 1-2 months. | Percentage of eyes with an APE of 0.50D or less |
| Contrast sensitivity | pre-operation | Contrast sensitivity will be evaluated using the Pelli-Robson Chart |
| Mean refractive outcomes | 3 months | Mean refractive outcomes (error and MRSE) will be evaluated |
Countries
Canada
Contacts
Primary ContactPaul Harasymowycz
Outcome results
None listed